PDCD1 and neoplasm: Immunotherapy focuses on identifying and attacking tumor cells by activating or enhancing the patient’s immune system, the most representative of which are programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors (5).